Literature DB >> 9203990

Prolactin receptors in human meningiomas: characterization and biological role.

G Muccioli1, C Ghè, G Faccani, M Lanotte, M Forni, E Ciccarelli.   

Abstract

Sixty cerebral meningioma specimens obtained at surgery from 34 female and 26 male patients were examined for the presence of prolactin (PRL) receptors. These were compared with normal arachnoid tissue from which these tumours arise. PRL receptors were detected in 61.7% of meningiomas whereas no PRL binding was found in samples of normal arachnoid tissue. No relationship was found when sex or histological findings were compared with the presence of PRL receptors. Receptor-positive tumours had saturable and high-affinity (Kd, 4.8 +/- 0.5 ng/ml) receptors with hormonal specificity for human PRL (hPRL) resembling that of other target tissues of PRL in man. The biological role of these receptors was investigated in primary cell cultures derived from meningioma tissue characterized for PRL receptor. When human PRL was added to the culture medium, in doses ranging from 1 to 200 ng/ml, a dose-dependent stimulation of 3H-thymidine incorporation was observed only in PRL-receptor positive tumours. The PRL concentrations required to produce a half-maximal effect ranged from 11 to 20 ng/ml and were quite close to the dissociation constant (Kd) of binding of PRL to its receptors. PRL also caused an increase of cell number compared with control with a significant effect after 3 and 4 days of culture. In conclusion, these findings indicate that a large number of human meningiomas express specific and functional receptors for PRL which are involved in mediating its proliferative effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203990     DOI: 10.1677/joe.0.1530365

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

1.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 2.  Surgical indications for pituitary tumors during pregnancy: a literature review.

Authors:  Thomas Graillon; Thomas Cuny; Frédéric Castinetti; Blandine Courbière; Marie Cousin; Frédérique Albarel; Isabelle Morange; Nicolas Bruder; Thierry Brue; Henry Dufour
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

Review 3.  Pathogenesis of peri-tumoral edema in intracranial meningiomas.

Authors:  Moncef Berhouma; Timothee Jacquesson; Emmanuel Jouanneau; François Cotton
Journal:  Neurosurg Rev       Date:  2017-08-24       Impact factor: 3.042

Review 4.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

5.  Pituitary adenoma associated with intraventricular meningioma: case report.

Authors:  Leodante B da Costa; Jay Riva-Cambrin; Asheesh Tandon; Michael Tymianski
Journal:  Skull Base       Date:  2007-09

6.  Foramen magnum meningioma: Dysphagia of atypical etiology.

Authors:  Gabriel J Tsao; Matthew W Tsang; Bret C Mobley; Walter W Cheng
Journal:  J Gen Intern Med       Date:  2007-12-15       Impact factor: 5.128

Review 7.  Unique features of pregnancy-related meningiomas: lessons learned from 148 reported cases and theoretical implications of a prolactin modulated pathogenesis.

Authors:  Yosef Laviv; Victoria Ohla; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2016-06-16       Impact factor: 3.042

Review 8.  Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review.

Authors:  Ryuya Yamanaka; Eisuke Abe; Toshiteru Sato; Azusa Hayano; Yasuo Takashima
Journal:  Cancers (Basel)       Date:  2017-08-08       Impact factor: 6.639

9.  Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation.

Authors:  Erdogan Pekcan Erkan; Thomas Ströbel; Christian Dorfer; Markus Sonntagbauer; Andreas Weinhäusel; Nurten Saydam; Okay Saydam
Journal:  Front Oncol       Date:  2019-10-10       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.